Detalles de la búsqueda
1.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol
; 24(1): 64-76, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36528035
2.
Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders.
Br J Haematol
; 201(4): 628-639, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36806152
3.
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment.
Haematologica
; 107(6): 1410-1426, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34670358
4.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34774221
5.
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
Cancer
; 127(18): 3413-3421, 2021 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34181755
6.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Haematologica
; 105(7): 1937-1947, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31582542
7.
Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide.
Biol Blood Marrow Transplant
; 24(1): 119-126, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29024804
8.
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
Ann Hematol
; 92(10): 1309-18, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23686116
9.
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents.
Antioxidants (Basel)
; 12(2)2023 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36830052
10.
Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome.
Am J Hematol
; 92(6): E117-E119, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28316085
11.
Radiomics and Artificial Intelligence for Outcome Prediction in Multiple Myeloma Patients Undergoing Autologous Transplantation: A Feasibility Study with CT Data.
Diagnostics (Basel)
; 11(10)2021 Sep 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34679456
12.
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 39(32): 3613-3622, 2021 11 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34520219
13.
Amino acid depletion triggered by Ê-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death.
Blood Adv
; 4(18): 4312-4326, 2020 09 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32915979
14.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol
; 7(6): e456-e468, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32359506
15.
The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience.
Ann Hematol
; 88(9): 855-61, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19189105
16.
Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa.
Oncol Rep
; 21(4): 1045-52, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19288007
17.
Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma.
Blood Adv
; 7(14): 3472-3478, 2023 07 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36897214
18.
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
Blood Cancer J
; 11(12): 197, 2021 12 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34876566
19.
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.
Leuk Lymphoma
; 52(10): 1961-9, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21942328
20.
Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis.
Oncol Lett
; 2(2): 289-295, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22866079